Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence by Hernandez-Flores, Georgina et al.
RESEARCH ARTICLE Open Access
Pentoxifylline sensitizes human cervical tumor
cells to cisplatin-induced apoptosis by
suppressing NF-kappa B and decreased cell
senescence
Georgina Hernandez-Flores
1, Pablo C Ortiz-Lazareno
1, Jose Manuel Lerma-Diaz
1, Jorge R Dominguez-Rodriguez
1,
Luis F Jave-Suarez
1, Adriana del C Aguilar-Lemarroy
1, Ruth de Celis-Carrillo
1, Susana del Toro-Arreola
2,
Yessica C Castellanos-Esparza
1 and Alejandro Bravo-Cuellar
1,3*
Abstract
Background: Worldwide, cervical cancer is the second most common causes of cancer in women and represents
an important mortality rate. Cisplatin (CIS) is a very important antitumoral agent and can lead tumor cells toward
two important cellular states: apoptosis and senescence. In some types of cancers pentoxifylline (PTX) sensitizes
these cells to the toxic action of chemotherapeutics drugs such as adriamycin, inducing apoptosis. In the present
work, we studied in vitro whether PTX alone or in combination with CIS induces apoptosis and/or senescence in
cervix cancer HeLa and SiHa cell lines infected with HPV types 16 and 18, respectively, as well as in immortalized
keratinocytyes HaCaT cells.
Methods: HeLa (HPV 18+), SiHa (HPV 16+) cervix cancer cells and non-tumorigenic immortalized HaCaT cells
(control) were treated with PTX, CIS or both. The cellular toxicity and survival fraction of PTX and CIS were
determinate by WST-1 and clonogenic assays respectively. Apoptosis, caspase activation and phosphorylation of
ERK1/2, p38, p65 (NF-B), Bcl-2 and Bcl-XL anti-apoptotic proteins were determinated by flow cytometry.
Senescence by microscopy. Phosphorylation of IBa and IB total were measured by ELISA. Pro-apoptotic, anti-
apoptotic and senescence genes, as well as HPV-E6/7 mRNA expression, were detected by RT-PCR.
Results: Our results show that after 24 hours of incubation PTX per se is toxic for cancer cells affecting cell viability
and inducing apoptosis. The toxicity in HaCaT cells was minimal. CIS induces apoptosis in HeLa and SiHa cells and
its effect was significantly increases when the cells were treated with PTX + CIS. In all studies there was a direct
correlation with levels of caspases (-3, -6, -7, -9 and -8) activity and apoptosis. CIS induces important levels of
senescence and phosphorylation of ERK1/2, p38, p65/RELA, and IBa, and decreased the expression of anti-
apoptotic protein Bcl-XL. Surprisingly these levels were significantly reduced by PTX in tumor cells, and at the same
time, increases the expression of pro-apoptotic genes.
Conclusion: PTX sensitizes cervical cancer cells to CIS-induced apoptosis and decreases the CIS-induced
senescence in these cells via inhibition of NF-B signaling pathway; diminishes expression of antiapoptotic proteins
and the activation of caspases.
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Cervical cancer is a major health problem worldwide; it
is the second most frequent cause of cancer in women.
An estimated 500,000 new cases, were reported in 2008,
[1], among which the most important was the presence
of human papilloma virus (HPV) infection. High-risk
HPV types 16 and 18 are responsible for > 70% of cases
of cervix cancer [2,3].
Chemotherapy works in several ways. First, the cells
die by apoptosis, which is an irreversible state defined as
the genetically programmed cell death, consequently
controlled by the balance between proapoptotic and
antiapoptotic genes and characterized by cell shrinkage,
membrane blebbing, chromatin condensation and
nucleosomal DNA fragmentation. Apoptosis is the most
convenient manner of tumor cell elimination, because
this type of cell death is a final state and the tumor cell
does not represent any possible future danger and does
not induce inflammation [4-6]. Other tumoral cell
response to chemotherapy is the cellular senescence [7].
This cellular state is considered a general biological pro-
gram of permanent growth arrest and can be induced
by telomere shortening (growing old) or by injuries to
DNA such as those induced by chemotherapy which do
not involve telomere shortening (accelerated senes-
cence). In this state, the tumor cell cannot replicate.
T h i sw a st h er e a s o ni tw a sc o n s i d e r e do r i g i n a l l ya sa
protector mechanism against the development of neo-
plasia. However, recent data indicates that factors
secreted by senescent cells can also alter the microenvir-
onment, and enhance the tumor growth of neighboring
tumor cells, indicating that this protective mechanism
can act as a double-edged sword. Senescent cells exhibit
changes in morphological characteristics such as
enlarged and flattened cell shape and increased granu-
larity. This distinction is identifiable with considerable
specificity by the detection of b-galactosidase (SA-b-gal)
through by X-gal activity staining [8,9].
The antitumor drug Cisplatin (CIS) with clinical and
experimental efficiency is employed as a first-line che-
motherapeutic modality in the treatment of epithelial
malignancies, including lung, ovarian, testicular, cervix
cancer and others [10]. From a cell biology viewpoint,
the principal mechanism of CIS-induced damage to
tumors involves the interaction with DNA and activa-
tion of the mitogen-activated protein kinase (MAPK)
signaling pathway, which controls a wide spectrum of
cellular processes including growth, differentiation and
apoptosis [11].
Unfortunately, the chemotherapy’s efficiency is so far
from satisfactory due to the side effects and to the resis-
tance of tumor cells. Recent publications open the possi-
bility of increasing the efficiency of chemotherapy.
Pentoxifylline (PTX), 1-[5-oxohexyl]-3, 7-dimethyl-
xanthine] is a non-specific phosphodiesterase inhibitor
that has been routinely employed for circulatory diseases
for > 20 years. PTX is a potent inhibitor of tumor
necrosis factor-alpha (TNF-a) and the transcription fac-
tor NF-B. In this respect, our group reported that the
100% of lymphoma-bearing mice treated with PTX +
adriamycin, an anthracycline, survived for > 1 year after
receiving only one half of the therapeutic dosage of
adriamycin. Similarly, we also observed that PTX
increased the levels of apoptosis generated by adriamy-
cin in fresh leukemic cells of pediatric patients [12-14].
Sensitization of tumor cells to adriamycin by PTX is not
tumor type specific. Similar results were observed in
hematological and cervical cancer cell lines [15].
The aim of this work was to investigate whether PTX
can sensitize cervical cancer cells to apoptosis by means
of CIS and modify cellular senescence. Our results indi-
cate that in vitro, exposure of cervix tumor cells to
PTX-treatment prior to CIS enhances apoptosis levels
and reduces cell senescence.
Methods
Cell lines
HeLa (HPV-18+) and SiHa (HPV-16+) cervical cancer
cell lines and the spontaneously immortalized human
epithelial cell line HaCaT (used as non-tumorigenic con-
trol cells) were kindly provided by Dr. Boukamp (DKFZ-
Heidelberg, Germany). The presence of the human papil-
loma virus (HPV) type was confirmed by the Linear
array
® genotyping test (Roche). All of the cell lines were
maintained in vitro and propagated in Dulbecco’sm o d i -
fied Eagle’s culture medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum, 1X L-glutamine
(2 mM final concentration) and antibiotics (penicillin/
streptomycin). This medium will be referred to as
DMEM-S, and was incubated at 37°C in an humidified
atmosphere containing 95% air and 5% CO2.A l lo ft h e
previously mentioned products were obtained from
GIBCO™ Invitrogen Corporation (Carlsbad, CA, USA).
Drugs and experimental conditions
Cisplatin (CIS) was obtained from PISA Laboratories,
México, and stocked at 4°C for < 4 days and adjusted to
a desirable concentration with DMEM culture medium
immediately prior to utilization. Pentoxifylline (PTX)
(Sigma Chemical Co., Saint Louis MO, USA) was dis-
solved in a sterile saline solution 0.15 M at a concentra-
tion of 0.2 M and maintained at 4°C < 4 days.
Cell culture and in vitro treatments
HeLa, SiHa, and HaCaT cells suspended in DMEM-S at
concentrations of 1.5 or 2 × 10
6 cells/8 mL in
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Page 2 of 15exponential phase were seeded in p100 Petri dishes for
flow cytometry assays and senescence. For the survival
test and for ELISA-determined apoptosis, the cells were
cultured in 96-well plates at a concentration of 3 × 10
5
cells/well/200 μL (final volume). For clonogenic assays,
the cells were seeded at densities of 1 × 10
4 cells/2 mL
in 6-well plates. In all cases, the cells were cultured
overnight at 37°C in a humidified atmosphere contain-
ing 5% of CO2 and 95% air. The medium was then
replaced with DMEM-S. Then the cells were either trea-
ted with PTX 8 mM, or with CIS 4 μMo rP T X+C I S
(final concentrations). These doses of the individual
drugs utilized were chosen base on the result of dose-
response curves. These doses allow us to observe any
further reductions caused by drug combination. The
cells were incubated with PTX 1 hours prior to the
addition of CIS and 24 hours later the culture cells were
harvested. For gene expression study, the cells were
incubated with the drugs for only 3 hours.
Clonogenic cell survival in vitro
Cells were assayed for the cytotoxic effects of PTX or
CIS or PTX + CIS after cell survival according to the
established methods of performing the clonogenic assay.
Subconfluent cultures were exposed to the drugs for 6
hours. Then the cells were washed with PBS that was
preheated to 37°C, trypsinized and plated in 6-well
plates (100 cells/wells). After 15 days of incubation in
complete culture medium, the colonies were stained
with crystal violet after fixation with formaldehyde and
were counted manually. In each case results are
expressed as the survival fraction (SF), which was
obtained by dividing the number of colonies formed
after the treatment/number of cells seeded × PE. Plate
efficiency (PE), PE = (N
o of colonies formed/N
o of cells
seeded) × 100. Colonies (≥ 50 cells) usually appeared in
15 days. The number of colonies on control and drug-
treated plates were counted on an inverted-stage micro-
scope at 40-fold magnification. A minimum of 30 colo-
nies/plate was required for an experiment to be
considered evaluable for measurement of drug effect
[16].
Drugs interaction analysis
To determine the nature of the interaction between
PTX and CIS, the data from the clonogenic assay were
analyzed according to Chou and Talalay [17] using Cal-
cuSyn V2.0 software, (Biosoft, Cambridge, UK) [18,19].
For that, the drugs were combined at a constant ratio of
PTX and CIS of 2000:1. The interaction of drugs was
quantified determining a combination index (CI). CI <
or > 1 indicated synergy or antagonism respectively,
whereas a CI value of 1 indicates additivity [20].
WST-1 assay
Cell survival was measured utilizing WST-1/ECS solu-
tion (BioVision Research, Mountain View, CA, USA).
After 24 hours of incubation 10 μL/well of WST-1/ECS
reagent was added and incubated for another 3 hours.
Absorbance was measured on a microtiter plate reader
(Synergy™ HT Multi-Mode Microplate Reader, Biotek
Winooski, VT, USA) at 450 nm. Data are reported in
percentage of cell survival as compared with the respec-
tively untreated control group considered as 100%.
Early apoptosis and caspase activity detection methods
Cellular detection of annexin V, M30 (caspase -3,-6,-7
and-9) and caspase-8 activity was determined by flow
cytometry employing the fluorescein isothiocyanate con-
jugated monoclonal annexin V-FITC apoptosis kit
(annexin-V-FLUOS; Roche, Mannheim, Germany), M30
CytoDEATH™ Biotin antibody (Roche Mannheim, Ger-
many), and the fluorescein active caspase-8 staining kit
(Abcam, Cambridge, MA) respectively according to the
manufacturer instructions. For the three tests at least
20,000 events were analyzed for each sample in an
EPICS XL-MCL™ flow cytometer Beckman Coulter
model (Fullerton, CA, USA). Data were processed with
the System II software package (Beckman Coulter).
Apoptosis ELISA assays
In normal untreated and treated cell cultures, we deter-
mined cytoplasmic histone-associated-DNA-fragments
(mono- and oligonucleosomes) spectrophotometrically
(420 nm) utilizing Cell Death Detection ELISA
PLUS (Roche
Mannheim, Germany) according the manufacturer’s
instruction. Enrichment of mono- and oligonucleosomes
released into the cytoplasm was calculated: experimental
absorbance/corresponding control absorbance. The results
are expressed as the percentage of DNA fragmentation.
Acridine orange/ethidium bromide staining to detect late
apoptosis by Ultraviolet (UV)-microscopy
Briefly, the cells were stained, with ethidium bromide
(Sigma Chemical Co. Saint Louis MO, USA) and acri-
dine orange (Sigma Chemical Co. Saint Louis MO,
USA) (100 μg/mL each). Two hundred cells were
counted and the numbers of each of the following four
cellular states were recorded: i) Live cells with normal
nuclei (LN), bright green chromatin and organized
structure; ii) Apoptotic cells (A) with highly condensed
or fragmented bright green-yellow chromatin; iii) Dead
cells with normal nuclei (DN), bright red chromatin and
organized structure and iv) Dead cells with apoptotic
nuclei (DA) and bright orange chromatin, which were
highly condensed and fragmented. Apoptotic index (AI):
A + DA/LN + A + DN + DA × 100 [21].
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According to the manufacturer’s instructions senescence
was determined histochemically in treated and untreated
control cells by Senescence Detection Kit (BioVision
Mountain View, CA, USA) which detects b-galactosidase
activity (SA-b-gal) present in senescence cells. We
counted 300 cells of six microscopic fields to determine
the percentage of SA-b-gal stained positive cells identi-
fied by an intense blue stain in the membrane.
Protein extraction for IBa [pS32] and IBa (total)
15 × 10
6 cells were seeded in p150 culture Petri-dishes
and treated next day with PTX, CIS and PTX + CIS for
24 hours. After treatment, cells were harvested by scrap-
ing and lysed with RIPA buffer (0.5% deoxycholate, 0.5%
NP-40, 0.5% SDS, 50 mM Tris pH 7.4 and 100 mM
NaCl) containing protein inhibitors. Following sonica-
tion (15 pulses, 90% amp), protein extracts were
obtained after 30-min incubation at 4°C and 5-min cen-
trifugation at 14,000 rpm/4°C. Protein concentrations
were determined using BioRad DC Protein Assay Kit.
IBa [pS32] and IBa (total) ELISA
The levels of IBa[pS32] and IBa(total) protein were
determined in HeLa and SiHa treated and untreated
control cells employing a commercial ELISA kit (Invi-
trogen) at 450 nm according to the manufacturer’s
instructions. The results are expressed as optical density
(O.D).
Bcl-2, Bcl-XL protein expression and phosphorylation
state ERK1/2, p38 and p65 by flow cytometry
In normal untreated and treated cell cultures, we deter-
minated the Alexa Fluor
® 647mouse anti-human Bcl-2
and Alexa Fluor
® 647 mouse anti human Bcl-XL pro-
teins (Santa Cruz CA) and phosphorylated ERK1/2
(pT202/pY204) PE-Cy™7 mouse anti-human, Alexa
Fluor
® 488 mouse anti-human anti-phospho (P)-p38
(pT180/pY182) and Alexa Fluor
® 647 mouse anti-
human NF-B p65 (pS529) BD Biosciences by flow cyto-
metry. Cells were resuspended in PBS and stained
according to protocol to detecting protein or activation
of the phosphorylation state. An appropriate isotype
control was utilized in each test to adjust for back-
ground fluorescence, and results are reported as Mean
fluorescence intensity (MFI). For each sample, at least
20,000 events were acquired in a FACSAria-I cell sorter
(BD Biosciences). Data were processed with the FACS-
Diva software (BD Biosciences).
Quantitative real time PCR
Total RNA from both types of cells was obtained after 3
hours of incubation using the PureLink™ Micro-to-
Midi total RNA purification system (Invitrogen
Corporation, Carlsbad, CA, USA). First-strand cDNA
was synthesized from 5 μgo ft o t a lR N Au s i n gS u p e r -
script™ III First-Strand Synthesis Supermix (Invitrogen
Corporation, Carlsbad, CA, USA). Real Time PCR was
performed using a LightCycler
® 2.0 apparatus (Roche
Applied Science, Mannheim, Germany) and LightCycler-
FastStart DNA Master
PLUS SYBR Green I (Roche
Applied Science, Mannheim, Germany). Analysis of PCR
products was performed using LightCycler
® software
(Roche Applied Science, Mannheim, Germany). Data are
expressed as relative quantities using a reference gene
(Protein Ribosomal). Each sample was processed in tri-
plicate to verify the specificity of the amplification reac-
tion. Oligonucleotides (Invitrogen Corporation,
Carlsbad, CA, USA) used to amplify human IBa,P 6 5 /
R E L A ,B A D ,B A K ,B A X ,N O X A ,P U M A ,P 2 1 ,P 5 3 ,P 1 6 ,
MCL-1, BCL-XL, CASPASE-3, CASPASE-9, SURVIVIN,
E6 and E7 (HPV16 and HPV18) and L32 RIBOSOMAL
PROTEIN are shown in Table 1. Oligonucleotides were
designed using the Oligo V6 software. Gene sequences
were obtained from the GenBank Nucleotide Database
of the National Center for Biotechnology Information
http://www.ncbi.nlm.nih.gov.
Statistical analysis
Results of each experiment represent the means ± stan-
dard deviation (SD) of three independent experiments
carried out in triplicate. Student’s t-test was used for
statistical analyses a value of P < 0.05 was considered
significant. For the comparison of gene expression was
considered as significant differences values of ≥ 30%. In
some cases was calculated the Δ%t h a tr e p r e s e n tt h e
percent of increment or diminution in relation to com-
parative group.
Results
Effect of PTX and CIS, alone or in combination on cervix
cancer cell line
To evaluate the antiproliferative effects to different
schedules of PTX, CIS or PTX+C I St r e a t m e n t s ,i na
first step we determined the clonogenic assay, which is
ap r o v e nm e t h o dt os t u d yt h ec h e m o s e n s i t i v i t yt oa n t i -
tumor drugs. Table 2 shows a clearly dose-response
effect in CIS-treated HeLa cultures in which toxicity
increased with the dose. Surprisingly, PTX also had
cytotoxic effect per se, it was also dose-dependant,
because with the administered dose of 8 mM, the sur-
viving fraction was approximately 70% lower than that
of the untreated control group (P <0 . 0 5 ) .T h ec o m b i -
nation of both drugs also shows a similar dose-
response effect, reaching near 80% and 100% of toxi-
city with the two highest doses of PTX 8 and 16 mM
and CIS at 4 and 8 μM respectively P <0 . 0 5vs
untreated control cells. We carried out the same
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to those obtained from HeLa cells, but were slightly
less efficient. Finally, cells from the non-tumorigenic
cell line HaCaT were less sensitive with the different
treatments than tumor cells, and highest toxicity was
found at the highest dosage.
Likewise in Table 2 the interaction of both drugs at
different concentrations are shown. We found a syner-
gistic effect in HeLa and SiHa cells with the two lowest
doses. With the dose of PTX 8 mM + CIS 4 μM, the
drugs interaction can be considered as nearly additive.
Finally with highest dose we found a different
Table 1 Primer pair sequences.
Gene Primer pair sequences GenBank Accession No
IBa 5’GGA TAC CTG GAG GAT CAG ATT A 3’
5’CCA CCT TAG GGA GTA GTA GAT CAA T 3’ NM001278
P65/RELA 5’GCA GGC TCC TGT GCG TGT CT 3’
5’GGT GCT CAG GGA TGA CGT AAA G 3’ NM02975
BAD 5’CTC CGG AGG ATG AGT GAC GAGT 3’
5’ACT TCC GCC CAT ATT CAA GAT 3’ NM004322
BAK 5’CGC TTC GTG GTC GAC TTC AT 3’
5’AGA AGG CAA AGA CTT CGC TTA 3’ NM001188
BAX 5’TTT GCT TCA GGG TTT CAT CC 3’
5’CAG TTG AAG TTG CCG TCA GA 3’ NM138764
NOXA 5’GAG ATG CCT GGG AAG AAG G 3’
5’TCC TGA GCA GAA GAG TTT GGA 3’ NM021127
PUMA 5’ GAT GGC GGA CGA CCT CAA C 3’
5’TGG GAG TCC AGT ATG CTA CAT GGT 3’ NM014417
P21 5’CGA CTT TGT CAC CGA GAC AC 3’
5’CGT TTT CGA CCC TGA GAG T 3’ NM000389
P53 5’CTG AGG TTG GCT CTG ACT GTA CCA CCA TCC 3’
5’CTC ATT CAG CTC TCG GAA CAT CTC GAA GCG 3’ NM000546
P16 5’CAG TAA CCA TGC CCG CAT AGA T 3’
5’TGA AAA GGC AGA AGC GGT GT 3’ NM000077
MCL-1 5’CAC GAG ACG GTC TTC CAA GGA TGC T 3’
5’CTA GGT TGC TAG GGT GCA ACT CTA GGA 3’ NM021960
BCL-XL 5’GCA GGC GAC GAG TTT GAA CT 3’
5’GTG TCT GGT CAT TTC CGA CTG A 3’ NM138578
CASPASE 3 5’ATA CTC CAC AGC ACC TGG TTA T 3’
5’AAT GAG AGG GAA ATA CAG TAC CAA 3’ NM004346
CASPASE 9 5’GTA CGT TGA GAC CCT GGA CGA C 3’
5’GCT GCT AAG AGC CTG TCT GTC ACT 3’ NM001229
SURVIVIN 5’TGA GCT GCA GGT TCC TTA TCT G 3’
5’GAA TGG CTT TGT GCT TAG TTT T 3’ NM001168
DIABLO 5’TGA CTT CAA AAC ACC AAG AGT A 3’
5’TTT CTG ACG GAG CTC TTC TA 3’ NM019887
E6 (HPV 18) 5’GCG ACC CTA CAA GCT ACC TGA T 3’
5’GCA CCG CAG GCA CCT TAT TA 3’ X05015
E7 (HPV 18) 5’TGT CAC GAG CAA TTA AGC GAC T 3’
5’CAC ACAAAG GAC AGG GTG TTC A 3’ X05015
E6 (HPV 16) 5’CAG AGC TGC AAA CAA CTA TAC 3’
5’AGT GGC TTT TGA CAG TTA ATA C 3’ NC001526
E7 (HPV 16) 5’GAC AAG CAG AAC CGG ACA G 3’
5’ATT CCT AGT GTG CCC ATT AAC A 3’ NC001526
L32 RIBOSOMAL 5’GCA TTG ACA ACA GGG TTC GTA G 3’
PROTEIN 5’ATT TAA ACA GAA AAC GTG CAC A 3’ NM000994
Oligonucleotides were designed using the Oligo v.6 software. Gene sequences were obtained from the GenBank Nucleotide Database of the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov).
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antagonic effect. However at highest dose in SiHa cells
it was observed a synergic effect. In non-tumorigenic
HaCaT cells with highest dose showed a synergic effect
and with other doses a nearly additive effect was
found.
Survival Cells in vitro
The survival index was determined by WST-1 assay and
we found 63.6 ± 2.1% and 57.8 ± 1.0% in HeLa and
SiHa cells exclusively treated with PTX respectively.
Surprisingly, survival was higher in HeLa cells (98.6 ±
10.5%) and SiHa cells (85.6 ± 9.2%) treated with CIS,
than in the groups treated solely with PTX. The most
important toxic effect was observed in PTX + CIS
groups. Cell survival after treatment was 40.2 ± 1.0% in
HeLa and 33.0 ± 1.2% in SiHa cells (P <0 . 0 0 1vs PTX
or CIS groups). In contraposition, the addition of CIS to
non-tumor HaCaT cells exhibited practically no effect
on their survival rate, and the PTX or PTX + CIS treat-
ments slightly decreased the surviving cells (74.1 ± 1.2%
and 78.5 ± 1.1% respectively). These data demonstrate
that PTX per se possesses toxic properties and produces
a significant increase of CIS cytotoxicity in human HeLa
and SiHa cervical cancer cell lines.
Early detection of apoptosis in cervix cancer cells
Early-stage of apoptosis was detected by flow cytometry
using annexin V and apoptosis progresses by DNA frag-
ments Enzyme-linked immunosorbent assay (ELISA).
Table 3 displays results for both tests. All groups
showed excellent correlation between both tests. We
then observed the same behaviour as in preceding
experiment, higher toxicity with the drug combination
in comparison with PTX, CIS or control treatments in
SiHa cells P < 0.001. PTX induces early apoptosis in
HeLa cells. In contrast, PTX alone in non-tumor HaCaT
cells did not induce early apoptosis in these cells. The
most important induction of early apoptosis was
observed only in the CIS-treated group (P <0 . 0 0 1i n
CIS vs PTX and untreated control group). Finally,
HaCaT cells cultures in the presence of PTX + CIS
exhibited an early apoptosis level comprising that
between CIS and untreated control cells.
PTX sensitizes cervical cancer cells to CIS-induced late
apoptosis induced through caspase activation
Apoptosis can be reversible in the first steps; for this
reason we also determined late apoptosis by epifluores-
cence. Figure 1A shows that in all cases in untreated
control groups, the apoptotic index was ≤ 13. In con-
trast, in all treated groups, important levels of apoptosis
were detected, because when HeLa and SiHa tumor
cells were treated with PTX alone, the apoptotic indexes
were 43.8 ± 4.4 and 46.2 ± 2.4 respectively (P < 0.001 vs
untreated group). The apoptotic index induced by CIS
alone in HeLa (36.8 ± 3.8) and SiHa cells (32.6 ± 2.9)
were slightly lower than those obtained with PTX alone,
Table 2 Cytotoxic effect of PTX and CIS either alone or in
combination on HeLa, SiHa and HaCaT cells.
Agent/combination Concentration Surviving fraction CI
HeLa cells
Pentoxifylline (mM) 2 0.95
4 0.44
8 0.23
16 0.00
Cisplatin (μM) 1 0.97
2 0.87
4 0.80
8 0.08
Pentoxifylline + Cisplatin 2 + 1 0.85 0.795
4 + 2 0.68 0.605
8 + 4 0.20 0.974
16 + 8 0.05 1.766
SiHa cells
Pentoxifylline (mM) 2 0.95
4 0.54
8 0.23
16 0.14
Cisplatin (μM) 1 0.94
2 0.72
4 0.65
8 0.10
Pentoxifylline + Cisplatin 2 + 1 0.70 0.753
4 + 2 0.56 0.380
8 + 4 0.28 0.970
16 + 8 0.005 0.840
HaCaT Cells
Pentoxifylline (mM) 2 0.90
4 0.87
8 0.83
16 0.75
Cisplatin (μM) 1 0.90
2 0.80
4 0.78
8 0.40
Pentoxifylline + Cisplatin 2 + 1 0.86 1.013
4 + 2 0.75 1.010
8 + 4 0.80 1.090
16 + 8 0.05 0.760
Clonogenic assays were assayed for the cytotoxic effects of PTX or CIS or PTX
+ CIS. Subconfluent cultures were exposed to the drugs for 6 hours. Then the
cells were washed, trypsinized and plated in 6-well plates. After 15 days of
incubation, the colonies were stained and counted manually. In each case
results are expressed as the surviving fraction. The drug interaction was
analyzed according to Chou and Talalay determining a combination index (CI).
CI < or > 1 indicated synergy or antagonism respectively, whereas a CI value
of 1 indicates additivity. The results represent the mean of three independent
experiments carried out in triplicate.
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tively (P < 0.001). Interestingly, the most important
indexes of apoptosis were obtained with the combina-
tion of PTX + CIS reaching for HeLa an apoptotic
index of 59.8 ± 1.8 and for SiHa cells 47.2 ± 2.9 (P <
0.001 vs untreated cells). In contrast, in HaCaT cells
treated with PTX, CIS or its combination, apoptotic
indexes were similar to those untreated cells.
It is well known that caspases play a central role in
apoptosis, because that we studied the caspases activa-
tion pathways. Participation of caspases-3,-6,-7 and -9
was determined by flow cytometry using M30 antibody.
In Figure 1B it can be observed that the three untreated
cells lines displayed minimal caspases activity (≤ 5.0%).
PTX culture exposure increases by 17.2 times the per-
centage of M30 positive cells in HeLa and by 5.8 times
in SiHa (P <0 . 0 0 1vs untreated cells). CIS induces an
increase of caspase activation in HeLa cells of 6.2 times
higher than in untreated cells and had no effect in SiHa
cells. However, in PTX + CIS-treated cells, we found a
clear additive effects in both cervical tumor cell lines,
observing a increment of positive cells to caspase activ-
ity of 23.3 and 6.5 times higher, respectively, than of
untreated control cells (P < 0.001 vs untreated cells).
In Figure 1C, it can observe that untreated group of
HeLa and SiHa cells displayed minimal caspase-8 activ-
ity, but when these cells were treated with PTX, we
found increments of caspase-8 activity to be 4.2 and 2.7
fold higher in HeLa and SiHa cells, respectively (P
<0.001 vs untreated cells), also CIS alone induces an
increase of caspase-8 activity but lower that the incre-
ment induced by PTX (HeLa 1.71 and SiHa 1.9 times
higher than corresponding untreated cells). The higher
increments on caspase-8 activity was found in PTX +
CIS treated groups were this treatment HeLa and SiHa
reached increments of 5.1 and 3.2 times higher than the
CIS treated group (P < 0.001).
PTX decreases CIS-induced senescence
Senescence was measured by determination of the b-
galactosidase. In all untreated cell lines studied, the
Table 3 Early apoptosis in HeLa, SiHa, or HaCaT cells
after in vitro exposure to pentoxifylline or cisplatin
either alone or in combination.
HeLa
GROUP ANNEXIN V ELISA
(% mean ± SD) (% mean ± SD)
CONTROL 3.7 ± 1.0 10.0 ± 1.5
PTX 8 mM 30.5 ± 1.1 * 30.3 ± 2.3 *
CIS 4 μM 10.9 ± 1.4 * 10.0 ± 2.3 *
PTX + CIS 25.2 ± 1.3 * 20.1 ± 2.5 *
SiHa
GROUP ANNEXIN V ELISA
(% mean ± SD) (% mean ± SD)
CONTROL 3.7 ± 1.0 10.0 ± 1.5
PTX 8 mM 28.4 ± 2.1 * 20.5 ± 1.8 *
CIS 4 μM 17.0 ± 0.2 * 17.5 ± 2.7 *
PTX + CIS 35.2 ± 1.0 * 30.5 ± 1.5 *
HaCaT
GROUP ANNEXIN V ELISA
(% mean ± SD) (% mean ± SD)
CONTROL 3.8 ± 0.2 10.0 ± 1.5
PTX 8 mM 6.0 ± 0.7 10.3 ± 1.8
CIS 4 μM 16.3 ± 0.7 * 20.1 ± 2.3 *
PTX + CIS 13.5 ± 1.0 * 15.4 ± 1.5 *
Cell cultures were treated with PTX or CIS or their combination, 24 hours later
the cells were harvested and early apoptosis was determined by flow
cytometry (annexin V-FITC) or ELISA kit (DNA-histone nucleosome). The results
represent the mean ± SD of three independent experiments carried out in
triplicate. Statistical analysis Student t test. (*) P< 0.001 vs untreated control
cells.
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Figure 1 Determination of late apoptosis and caspase activity
of HeLa, SiHa and HaCaT cells after in vitro treatment with
pentoxifylline or cisplatin either alone or in combinations.2 4
hours later the cells were harvested and late apoptosis was
determined by UV light microscopy using ethidium bromide and
acridine orange stains, the results represent late apoptosis index
(Figure 1A). Caspases-3, -6, - 7, -9 and -8 activation was determined
by flow cytometry, the results represent the percentage of caspase
activity (Figure 1B and 1C respectively). The results represent the
mean ± SD of three independent experiments carried out in
triplicate. Statistical analysis, Student’s t test. (*) P < 0.001 vs CTL. (♦)
P < 0.001 vs CIS.
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Page 7 of 15percentage of senescence was minimum (≤ 12.1 ± 0.6%)
(Figure 2). It is noteworthy that PTX does not induce
senescence in all cell lines. In opposite fashion, CIS
induced high levels of senescence in comparison with
untreated control cells: 6.9 times higher in HeLa (83.3 ±
4.1%) and in SiHa cells (81.5 ± 4%), and in both cases P
<0 . 0 0 1vs the untreated control group. CIS does not
modify the percentage of senescence in HaCaT cells. In
HeLa and SiHa cells treated with PTX + CIS the per-
centage of SA-b-Gal(+) was significantly lower (22.9 ±
7.5% and 27.2 ± 5.4%, respectively) which represents a
3.6 and 3-times lower diminution in relationship to
senescence induced by CIS alone (P < 0.001).
Total IBa and IBa Phosphorylated in serine 32 (IB-
pS32)
As a central point, in this set of experiments we quantified
the total IBa and the phosphorylated form. Our observa-
tions in Figure 3c learly showed that with both cervical
tumor cells, all treatments increased total IBa in relation-
ship to the phosphorylated form IBa from untreated con-
trol groups, respectively, except in TNF-a treated cultures
(P < 0.001). In all PTX-treated groups, the phosphorylated
form with both tumor cell lines was diminished in compar-
ison with the respective untreated control groups (P <
0.001). In contraposition, and again in both tumor cell
lines treated with TNF-a or CIS, the phosphorylated frac-
tion was drastically incremented (P < 0.001 vs CTL, PTX).
Likewise the PTX diminished the phosphorylation of IBa
induced by CIS or TNF-a P <0 . 0 0 1 .
Phosphorylated ERK1/2, p38 and p65 determination
On the other hand when the cells are stressed by che-
motherapy the phosphorylation of ERK1/2, p38 and
p65 (NF-B subunit) proteins play a central role in cell
proliferation, differentiation, and survival. Under our
experimental conditions, these proteins were deter-
mined by flow cytometry and the results are reported
as Mean fluorescence intensity (MFI). In Figure 4 we
can observe that pERK1/2 expression in HeLa, SiHa
and HaCaT decreased in cells treated with PTX com-
pared with untreated group (P < 0.001). In SiHa cells,
CIS increased phosphorylation of ERK1/2 and PTX +
CIS-treated group decreased this phosphorylation (P <
0.001).
Expression of phosphorylated p38 in HeLa and SiHa
tumor cells was inhibited significantly in the cells har-
vested, from PTX alone and PTX + CIS treated cultures
(P < 0.001 vs CIS or untreated cells), while treatment
with CIS alone showed an MFI similar to that of the
respective untreated group in SiHa cell and an increased
in HeLa cells (P < 0.001). HaCaT cells did not differ sig-
nificantly among all groups.
We also determined the phosphorylation of p65 (NF-
B subunit). The behavior of HeLa and SiHa cells was
similar to that in previous experiments because PTX
alone or in combination with CIS significantly inhibited
the phosphorylation of p65 (P < 0.001) in comparison
with that of untreated cells and the CIS group. In HeLa
and SiHa cells, CIS increased p65 phosphorylation in
comparison with that untreated cells (P < 0.001). Finally
HaCaT cells did not modify the expression of phos-
phorylated p65 protein with any treatment. All groups
showed similar values to untreated control HaCaT cells.
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Figure 2 Determination of b-galactosidase-associated
senescence of HeLa, SiHa and HaCaT cells after in vitro
treatment with PTX or CIS either alone or in combinations.2 4
hours later the cells were harvested and senescence was
determined by histochemistry using senescence detection kit
(BioVision Mountain View, CA, USA). The results represent the mean
± SD of three independent experiments carried out in triplicate.
Statistical analysis, Student’s t test. (*) P < 0.001 vs CTL. (♦) P < 0.001
vs CIS.
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Figure 3 Phosphorylation of the IBa [pS32] and IBa (Total)
by ELISA kit of HeLa and SiHa cells after in vitro treatment
with pentoxifylline or cisplatin either alone or in combination.
24 hours later the cells were harvested and the phosphorylation of
the IBa [pS32] and IBa (Total) was determined by commercial
ELISA kit (Invitrogen). The results represent the mean ± SD of three
independent experiments carried out in triplicate. Statistical analysis
Student’s t test. (*) P< 0.001 vs CTL. (￿) P< 0.001 vs TNF-a.( ♦) P
<0.001 vs CIS.
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Page 8 of 15PTX decreased Bcl-2 and Bcl-XL anti-apoptotic proteins
NF-B pathway regulates the anti-apoptotic proteins Bcl-2
and Bcl-XL. The elevated levels of these proteins confer
chemoresistance. Participation of Bcl-2 and Bcl-XL was
determinated by flow cytometry. Figure 5 shows that PTX
is able to markedly down-regulate the expression of Bcl-2
and Bcl-XL proteins in both HeLa and SiHa cells as com-
pared with untreated cells (P <0 . 0 0 1 ) .W eo b s e r v e da
decreased Bcl-XL protein expression in SiHa cells treated
with CIS in comparison to untreated cells (P < 0.05). The
group treated with a combination treatment of PTX + CIS,
a marked decrease in Bcl-2 and Bcl-XL was detected com-
pared with untreated cells or treated with CIS (P <0 . 0 5 ) .
PTX, CIS or PTX + CIS modifies caspase, proapoptotic and
antiapoptotic, senescence and NF-B related gene
expression
Real time-PCR was employed to determine mRNA expres-
sion (Figure 6). In PTX-treated HeLa cells, we found 1.3 to
3 fold up-regulation of IBa, P65/RELA, CASPASES-3
and -9, P21, BAK and NOXA. In PUMA gene expression,
we found a > 28 fold up-regulation with PTX. When the
cells were treated with CIS, we observed 1.3 to 3 fold up-
regulation of P53, P16, BAX, BAD, BAK, NOXA, CAS-
PASES-3, -9, IBa,P 6 5 / R E L A ,B C L - XL and MCL-1, P21
and PUMA. In PTX + CIS treated HeLa cells we observed
1.3 to 3 fold up-regulation of IBa, P65/RELA, P53, BAK,
BAX, BAD, P16 and MCL-1 up-regulation of > 3-fold in
CASPASES-3, -9, NOXA and P21. However, the up-regu-
lation was greater in PUMA (45 fold). PTX-treated SiHa
cells demonstrate 1.4- to 3-fold up-regulation in CAS-
PASE-3, P53, P16 and P21 genes and an increase of > 3-
fold in CASPASE-9. In the same manner, CIS induced a
1.3- to 3-fold up-regulation of CASPASES-3, -9, P21,
NOXA, P16 and DIABLO. When SiHa cells were treated
with PTX + CIS, mRNA expression levels of P53 and
PUMA, and P16 were 1.3- to 3-fold up-regulated, while in
CASPASES-3, -9, NOXA and P21 we found > 3-fold up-
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Figure 4 Determination of phosphorylated ERK 1/2, p38, and p65 in HeLa, SiHa and HaCaT cell treatment with pentoxifylline or
cisplatin either alone or in combination. 24 hours later the cells were harvested and the phosphorylated ERK1/2, p38 and p65 proteins were
determined by flow cytometry. A total of 20,000 events were registered in each test. The results represent the mean ± SD of 3 independent
experiments carried out in triplicate. (*) P< 0.001 vs untreated control cells. (♦)=P< 0.001 vs CIS.
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Page 9 of 15regulation. Finally, in CIS-treated HaCaT cells, we found
1.3- to 3-fold up-regulation in CASPASES-3, -9, BAX,
BAD, NOXA, P16 and MCL-1 and one of > 5-fold in P65,
P53, PUMA, BAK, P21 and BCL-XL. When the HaCaT
cells were treated with PTX + CIS, we found a 1- to 3-fold
increase in MCL-1 gene and > 2.5-fold in NOXA, BAD,
P65/RELA, PUMA and BCL-XL. Moreover, we observed >
20-fold increase in BAX and a 60-fold in P21 genes; in
contrast, P53 was inhibited 1.3-fold. With these treatment
schedules, the data in general suggested that activation is
in favor of genes with proapoptotic activity in PTX + CIS-
treated HeLa and SiHa cancer cells.
Expression of E6 and E7 mRNA from HPV 16 and 18 on
HeLa and SiHa cells respectively, determined by real-time
PCR
E6 and E7 play a key role in cervical carcinogenesis. We
analyzed, in human cervical carcinoma cell line HeLa
and SiHa, the gene expression of the viral oncogenic E6
and E7. This set of experiments was performed under
the same experimental conditions, and the results are
reported as the Δ% of the values obtained, taking as
100% the expression of the constitutive ribosomal
mRNA. In the case of HPV-18 positive HeLa cells, the
expression of E6-E7 mRNA was modified only in the
PTX + CIS-treated group, which achieved an increase of
Δ% = 22. For the case of E7 mRNA expression, we
observed in the same line a slight decrease (Δ% ≤ 12%
for PTX- and CIS-treated groups) and no variation was
observed in PTX + CIS-treated group. The mRNA
expression of E6 and E7 in SiHa cells (HPV-16+) was
significantly inhibited in relation to untreated control
group, because for E6 mRNA expression was Δ%=- 4 8 ,
-59 and -58% from culture cells treaded with PTX, CIS
and PTX + CIS, respectively, while for E7 mRNA
expression, Δ% was -42, -65 and -60% respectively.
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Figure 5 Determination of Bcl-2 and Bcl-XL anti-apoptotic proteins in cervical tumor cells treated with PTX or CIS either alone or in
combination. 24 hours later the cells were harvested and the proteins expression were determined by flow cytometry. A total of 20,000 events
were registered in each test. The results represent the mean ± SD of 3 independent experiments carried out in triplicate. (*) = P < 0.01 vs CTL.
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In the present work, we found good correlation between
survival and different apoptotic assays. Surprisingly,
PTX per se results toxic for HeLa and SiHa tumor cells
and sensitizes these to the toxic action of CIS, increas-
ing apoptosis and simultaneously reducing senescence.
It is also noteworthy that as an advantage, PTX is more
toxic than CIS in cancer cells and was practically not
toxic for non-tumorigenic HaCaT keratinocytes.
We detected early and late apoptosis because in the
first steps apoptosis can be reversible [22]. The UV light
microscopy test allowed us to appreciate a definitive sta-
tus. The observation that non-tumorigenic HaCaT cells
are less sensitive to different treatments is probably due
to the fact that the rate of multiplication and metabo-
lism is slower in HaCaT cells than in tumor cells.
These results are in agreement with other published
data reporting that PTX sensitizes in vivo and in vitro
cancer cells to chemotherapy, particularly to adriamycin
[12]. Within this context, we previously reported that the
PTX is able to sensitize lymphoma and leukemic cancer
cells to apoptosis by adriamycin or perillyl alcohol [13].
Similar results have been reported with radiotherapy
[23]. The observations of the present work are in agree-
ment with recent data in which our group demonstrated
that PTX increases apoptosis and inhibits senescence in
HeLa and SiHa Cells treated with adriamycin, an anthra-
cycline used also against cervical cancer [15]. The present
results are important because CIS is the first drug of elec-
tion in the treatment of cervical cancer. Additionally to
published data, the results of the present work strongly
suggest that the cytotoxicity of PTX is not limited to one
type of tumor cells or to chemotherapeutic drugs, incre-
menting its potential utilization in Oncology.
The low toxicity showed by CIS in survival test may
be explained because CIS induces senescence.
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Figure 6 Changes in the expression of caspases, senescence, NF-B, pro- and antiapoptotic-related genes after in vitro exposure to
pentoxifylline or cisplatin either alone or in combination. The gene expressions were determined by real-time quantitative PCR. The data
are expressed as mRNA fold-increase using mRNA ribosomal as a reference gene. Experiments were conducted in triplicates and repeated three
times. In all cases, SD was not > 0.08.
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Page 11 of 15Senescence originally was considered to be a tumor-sup-
pressor mechanism [24,25]. However its role in Oncol-
ogy is not clear because senescent cells though they
cannot replicate, continue releasing growth factors,
enzymes and other products that under certain condi-
tions promote tumor growth [9,26]. It is very interesting
t h a tP T Xd o e sn o ti n d u c es e n e s c e n c e ,a n ds t r o n g l y
decreases the senescence induced by CIS. The impor-
tance of these observations is that an antitumoral treat-
ment that induces principally apoptosis rather than
senescence is preferable in cancer cells.
Different mechanisms can explain our observations.
PTX also has antimetastatic activity [27] and arrests the
cell cycle in the G2/M, in which the tumors are more
sensitive to the toxic effects of some chemotherapeutic
and radiotherapeutic agents [28,29]. PTX has been
linked as well to the activation of caspase [12,30]. In
this study, an important activity of caspase (-3, -6 -7 -9
and -8) was detected in HeLa and SiHa cells treated
with PTX or PTX + CIS and, in minor degree, with CIS.
In addition, this caspase activity is directly proportional
to the level of apoptosis confirming its participation. In
SiHa cells treated with CIS alone, we observed low cas-
pase activity. In this regard, it has been reported that
CIS may also exert its apoptotic activity by caspase-
independent pathways [31].
PTX is a strong inhibitor of phosphodiesterase activ-
ity. In murine lymphoma and U937 human monocyte
cell line, it also prevents activation NF-B in these cells
[12] by inhibition of the phosphorylation of serine 32 in
IBc o m p l e x .T h u sp r e v e n t i n gT N F - a secretion and
expression of certain antiapoptotic genes that possess
antioxidant activity [32]. Contrariwise, CIS promotes the
formation of reactive oxygen species (ROS), which pro-
voke apoptosis or senescence [33].
We also studied the phosphorylation of different pro-
teins that are important for proliferation, differentiation,
cell survival, apoptosis and senescence such as ERK1/2
and p38 from the family of mitogen activated protein
kinases (MAPKs) and phosphorylation of the p65 subu-
nit of NF-Ba n dr e l a t e dI B proteins. Induction of
death by CIS has been associated with increase in p38
and ERK1/2 activity [11,34]. We observed this activity in
SiHa and HeLa cells, but it has been demonstrated that
ERK1/2 activity induced by CIS can cause resistance in
SiHa cells [35], gastric cancer cells [36], and human
myeloid leukemic cells [37]. PTX decrease ERK1/2
phosphorylation in SiHa cells, this disrupts resistance to
CIS, because when we utilized PTX, apoptosis was
higher than in CIS-treated cells. Is it noteworthy that,
PTX decreased the phosphorylation of p65 and IBa
(S32), thus resulting in the inhibition of nuclear translo-
cation of NF-B and avoiding the cell survival and resis-
tance observed in CIS-treated cells [38-40]. NF-B can
activate different genes related with the cell survival
such as Bcl-2 and Bcl-XL [41]. It’s important to stress
that PTX by itself or in combination with CIS disrupt
the NF-B pathway. We observe an inhibition of phos-
phorylation the IBa, p65 and decrease the levels of
anti-apoptotic proteins Bcl-2 and Bcl-XL in HeLa and
SiHa cells. This is important because these antiapoptotic
proteins confer resistance to several chemotherapeutic
agents including CIS, gemcitabine, vincristine, etoposide,
doxorubicin, and paclitaxel [42].
In our study, PTX significantly disrupted the CIS
resistance in HeLa and SiHa cell by blocking the NF-B
mediated survival pathway. PTX possesses an additive
effect with CIS (8 mM + 4 μM respectively); the com-
bined usage of these two drugs promotes apoptosis of
cervical tumor cells and at the same time impairs
senescence.
Our results suggest that PTX action on NF-B, ERK1/
2, p38, Bcl-2 and Bcl-XL proteins and caspases can
explain the fact that it does not induce senescence, but
does increase apoptosis in HeLa and SiHa cells. In addi-
tion, when we employed PTX in combination with CIS,
it impaired CIS-induced senescence and increased the
sensitivity of these cervix cancer cells to this drug.
Therefore, we think that PTX could be used to abrogate
NF-B-induced resistance mechanisms without severe
systemic toxicity. Thus, the use of PTX with other che-
motherapeutic agents such as CIS may lead to more effi-
cient cervical cancer cell elimination.
Moreover, a gene expression analysis to study the
antitumoral effects of drugs is critical in order to iden-
tify the potential PTX + CIS-specific genetic targets
involved. Employing an RT-PCR assay, we studied the
mRNA expression of genes related NF-B pathway,
apoptosis and senescence. In general, we observed in
HeLa and SiHa cervix cancer cells an up-regulation of
some proapoptotic genes after PTX + CIS treatment,
including the DIABLO, NOXA, PUMA, CASPASES-3
and -9 genes, which are implicated in the mitochondrial
pathway of apoptosis [43]. It is noteworthy that treat-
ment with CIS induces the expression of anti-apoptotic
gene, SURVIVIN. These phenomena have been reported
as another cause of tumor-cell resistance to chemother-
apy [44,45]. Up-regulation of SURVIVIN is also present
in senescent tumor cells. To the contrary, treatment
with PTX alone in all experimental groups, down-regu-
lated the expression of SURVIVIN gene. These results
show that PTX can overcome one of the survival strate-
gies used by the cancer cells in response to chemothera-
peutic agents. The Bcl-2 family genes protect the cells
of CIS-induced apoptosis [46,47]. This fact contributes
to the explanation of all our results because we found
that some survival genes are down-regulated by PTX, as
it the case with BCL-XL. The strongly over-expression
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Page 12 of 15of some pro-apoptotic genes likes PUMA (4500%), tip
the balance in favor of apoptosis. CIS administration
paradoxically leads to an antiapoptotic effect of p53
pathway, which induces tumor cell resistance to CIS
[48,49]. In our work, we demonstrated that PTX coun-
teracts this effect by promoting apoptosis in HeLa and
SiHa cells, as confirmed by the over-expression of
PUMA, NOXA and P21 genes which are regulated by
p53 [50]. This does not exclude the existence of other
p53-independent pathways for induction of apoptosis,
because we found a slight over-expression of P53 com-
pared with the high over-expression of NOXA, PUMA
and P21 genes [51-53]. It is important to remark that
these results together agree with the direct determina-
tion of the most important proteins related with apop-
tosis and the cell survival under our experimental
conditions. The senescence-associated P16 gene, exhi-
bits a different behaviour between two cancer cervix
lines. CIS induced up-regulation of the P16 gene in
HeLa and SiHa cancer cells, is incomplete accordance
to the senescence levels observed in b-galactosidase
assay in these cells.
With regard to IBa and P65/RELA genes, related to
transcription factor NF-B, IBa and P65 expression,
were down-regulated or remained unchanged with all
treatments in SiHa cells, suggesting a diminution of the
availability of these factors, which facilitate cell apopto-
sis. However, in the three treated groups of HeLa cells,
we observed an up-regulation of IBa and P65/RELA
genes strictly that was comparable between these genes
suggesting an equal balance of both factors.
In the non-tumorigenic line HaCaT we observed a dif-
ferent behaviour in comparison with cervical tumor
cells. In general, we noted an important activation of
genes with proapoptotic activity, including BAB, BAX,
NOXA and P21 (CIS and PTX + CIS), as well as in
PTX groups for CASPASE-3 gene. However, despite of
the up-regulation of several proapoptotic genes, apopto-
sis levels were low and cell viability was not affected,
suggesting that the rate of multiplication displays an
important effect in the action of the assayed drugs. In
this respect, is also important to mention that P65 is
up-regulated > 7-fold and BCL-XL 5-fold, and we found
no important levels of apoptosis.
Because expression of mRNA E6/E7 genes appear to
play a key role in cervical cancer development, we con-
ducted an analysis in human cervical carcinoma SiHa
and HeLa cell line. We observed a decrease in the
expression of E6 and E7 genes only in SiHa cells, treated
with the different drugs, although in HeLa cells we
observed no effect on these genes. In both cancer cell
lines, we observed induction apoptosis and sensibiliza-
tion by PTX. This indicates that several mechanisms of
resistance and susceptibility to antitumoral drug could
be implicated, such as the HPV types and their interac-
tions with the cells.
The choice between survival, senescence or apoptosis,
is a very complex process [54,55]. Rather than the action
of a single gene or molecules, the final balance between
activation or not of these genes and molecules deter-
mines whether or not a cell undergoes apoptosis. In this
study, we observed an overall balance in favor of the
apoptotic process in HeLa and SiHa cancer cells treated
with PTX and/or CIS.
Conclusions
Our observations show that PTX possesses antitumor
activity and inhibits cisplatin-induced senescence. The
novel combination of PTX + CIS which sensitizes HeLa
and SiHa cancer cells, to the toxic effect of CIS without
affecting the viability of non-tumorigenic cell line, may
be a promising approach to the treatment of patients
suffering from cervix cancer.
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